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Abstract
Objectives: In resource-constrained settings, tuberculosis (TB) is a common opportunistic infection and cause of death in
HIV-infected persons. TB may be present at the start of antiretroviral therapy (ART), but it is often under-diagnosed. We
describe approaches to TB diagnosis and screening of TB in ART programs in low- and middle-income countries.
Methods and findings: We surveyed ART programs treating HIV-infected adults in sub-Saharan Africa, Asia and Latin
America in 2012 using online questionnaires to collect program-level and patient-level data. Forty-seven sites from 26
countries participated. Patient-level data were collected on 987 adult TB patients from 40 sites (median age 34.7 years; 54%
female). Sputum smear microscopy and chest radiograph were available in 47 (100%) sites, TB culture in 44 (94%), and Xpert
MTB/RIF in 23 (49%). Xpert MTB/RIF was rarely available in Central Africa and South America. In sites with access to these
diagnostics, microscopy was used in 745 (76%) patients diagnosed with TB, culture in 220 (24%), and chest X-ray in 688
(70%) patients. When free of charge culture was done in 27% of patients, compared to 21% when there was a fee
(p = 0.033). Corresponding percentages for Xpert MTB/RIF were 26% and 15% of patients (p = 0.001). Screening practices for
active disease before starting ART included symptom screening (46 sites, 98%), chest X-ray (38, 81%), sputum microscopy
(37, 79%), culture (16, 34%), and Xpert MTB/RIF (5, 11%).
Conclusions: Mycobacterial culture was infrequently used despite its availability at most sites, while Xpert MTB/RIF was not
generally available. Use of available diagnostics was higher when offered free of charge.
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Introduction
Tuberculosis (TB) is the most common opportunistic infection
in HIV-infected patients in resource-limited settings and associated
with high mortality in patients who start antiretroviral combina-
tion therapy (ART) [1,2]. In high TB-incidence settings, TB may
frequently be present at ART initiation, but not always diagnosed,
and contributes significantly to mortality in the first weeks and
months of ART [3,4]. One risk factor for early mortality is an
unmasking or paradoxical immune reconstitution syndrome that
may occur after ART start, particularly in severely immunosup-
pressed patients [1,5–8].
The overall incidence of TB is substantially reduced with long-
term ART in both adults and children [2,9–11] but additional
interventions are needed to control TB in HIV-infected patients
including screening, improved diagnosis and preventive therapy
[12–14]. TB screening and diagnosis before starting ART is
important, since the initiation of ART shortly after the initiation of
TB treatment improves survival, particularly in patients with low
CD4 cell counts [15–17].
In a survey of 15 ART programs in 12 countries in Africa, the
Caribbean, Central and South America, as well as Asia, we
previously showed that the capacity of programs to diagnose TB
was often limited in 2008 [18]. Since then, new diagnostic tools for
rapid TB diagnosis have been introduced and have shown
promising results [19,20]. In 2012, we undertook a large scale
survey on the integration of TB and HIV services, diagnostic,
screening, preventive and treatment practices within the Interna-
tional epidemiologic Databases to Evaluate AIDS (IeDEA)
collaboration. Here, we report the results on the availability and
use of TB diagnostics across adult ART programs in low- and
middle-income countries, using both program-level and patient-
level data.
Methods
IeDEA includes networks of ART programs in low- and middle-
income countries from Africa, Asia, the Caribbean, Central and
South America, as well as North America [21–23]. Data are
collected at each site as part of routine monitoring at program
enrollment and each follow-up visit. We surveyed ART sites in
low- and middle-income countries participating in IeDEA across
Africa, Asia, the Caribbean, Central and South America between
March 1 and July 1, 2012. A total of 71 sites treating adults or
children were invited and 58 sites (81.7%) participated, including
11 pediatric sites treating children only. See File S1 and Table S1
in Supporting Information for a list of investigators and sites.
Data collection
Representatives from participating IeDEA regions and the TB
and pediatric working groups of IeDEA developed this project.
The survey was written in English, translated into French and
Spanish, and pilot-tested in both languages. Study data were
collected and managed using REDCap (Research Electronic Data
Capture) electronic data capture tools (see https://redcap.
vanderbilt.edu/) [24]. The survey consisted of three components:
Section A was an online questionnaire on integration of services,
diagnostic, screening, preventive and treatment practices related to
TB at the sites; Section B included eight clinical scenarios on TB
and HIV management to assess the practices of treating clinicians;
and Section C requested routinely collected data on consecutive TB
patients seen during the study period.
Section A was completed by local data managers or medical staff.
Data collected included site characteristics (level of care, urban or
rural setting, number of HIV patients actively followed-up,
number of TB cases seen), diagnostic and screening practices,
infection control measures, treatment schemes, prevention and
prophylaxis practices, integration of HIV and TB care, costs to
patients and TB case definitions. Availability was assessed as access
to the provider on site, within 5 km, within 10 km, within 20 km,
within 30 km, within 40 km, within 50 km, more than 50 km, or
not available. In Section B, treating physicians and clinical officers
at the sites were asked to address clinical scenarios for hypothetical
TB patients presenting at their clinic (Table S2). Treating
physicians were instructed that the answers should reflect current
practices at their treatment program and not necessarily the best
practice available. Sections A and B consisted of one questionnaire
per site. In Section C, we requested data on HIV-infected TB
patients consecutively seen from the start of the study period on
March 1 through to July 1, 2012, up to a maximum of 50 patients
per site. TB cases were defined based on the local case definition;
all received anti-TB treatment. Collected data included age, sex,
pregnancy status at time of TB diagnosis, date of enrollment into
HIV care, date of TB diagnosis, start date of TB treatment,
prescribed TB regimen, start date of ART, CD4 cell count, WHO
clinical stage at ART start, date of any previous TB episode, type
of screening, type of episode (new case, relapse, treatment after
failure, etc.), disease manifestation, sputum microscopy result,
culture result, nucleic acid amplification test result, clinical signs
and symptoms (coughing, night sweats, fever, weight loss), use of
tuberculin skin testing (TST) and isoniazid preventive therapy
(IPT). Seven sites from four regions (Asia-Pacific, Caribbean-
Central-South America, Central Africa, Southern Africa) did not
contribute individual-level patient data because the data collection
was not covered by the local IRB approval (four sites), or because
of logistical reasons (three sites).
Statistical analyses
The present analysis included ART programs treating patients
aged 16 years or older, and focused on TB diagnostics and
screening practices. Descriptive statistics were used to compare
characteristics of sites and TB patients. Variables of interest
included program-level characteristics (such as level of care,
setting, cumulative HIV cohort size, or availability of diagnostics),
clinical decision making using hypothetical clinical scenarios (such
as decision to conduct sputum smear microscopy, culture, or chest
X-ray), and individual-level patient data (such as age, sex, WHO
clinical stage, on ART or not when TB treatment started, use of
sputum smear microscopy, culture, Xpert MTB/RIF, or chest X-
ray to diagnose TB). We distinguished between the availability of
diagnostics (‘‘access’’) and how diagnostic tools were used at the
patient level at sites with access to the tools (‘‘use’’). We assumed
that there was access to a tool if it was available on or off site. We
used x2 tests or Fisher’s exact tests to assess differences between
groups in binary variables and the Wilcoxon rank sum test for
continuous variables. Results are presented overall and stratified
by IeDEA region. All analyses were performed in Stata version
11.2 (Stata Corporation, College Station, TX, USA).
Data sharing statement
The data held by the IeDEA consortium are available to other
investigators, based on a concept note describing the planned
analysis which was approved by the regional Steering Groups and, if
analyses involve several regions, by the Executive Committee of
IeDEA. Further details are provided at www.iedea.org/welcome-to-
iedea/working-groups/concept-sheets/iedea-multi-region-concepts-
principles-and-procedures.
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Ethics statement
Data were collected through IeDEA cohorts. Ethics committees
and/or Institutional Review Boards in all host countries approved
the collection and transfer of anonymized data (see File S2 in
Supporting Information for a complete list). Where requested per
local regulations informed consent was provided. In addition, the
Vanderbilt University Health Science Committee, Nashville,
Tennessee (USA), the Ethics Committee of the University of Bern
(Switzerland), and the University of Cape Town (South Africa)
approved the analyses of these observational data for this specific
project.
Results
Program and patient characteristics
Forty-seven ART sites from 26 countries treating adult HIV
patients were included (see map in Figure 1 and list in Table S1).
These sites treat more than 250,000 HIV-infected adult patients,
with almost 18,000 new TB cases diagnosed each year. Twenty-
four (51.1%) sites were tertiary care centers and 15 (31.9%) were
treating adults only (Table 1). Twenty-eight (59.6%) sites had a
specialized TB clinic or ward on site with dedicated staff, nine
(19.1%) sites had no specialized clinic, and 10 (21.3%) sites
referred TB patients elsewhere. Data on 987 adult TB patients
from 40 sites were available. In seven sites, investigators were
unable to collect patient data for this survey or no TB cases were
seen during the study period. The median age of TB patients was
34.7 years (interquartile range [IQR] 29.4–40.9) and 442 patients
(44.8%) were female. The median CD4 cell count at ART
initiation was 127 cells/mm3 (IQR 42–250), and 128 (13.0%)
patients had a history of previous TB. The median time between
TB treatment and ART initiation was 37 days (IQR 15–124). The
characteristics of patients are presented in Table S3.
Availability of diagnostics
Sputum smear microscopy and chest X-ray were available at all
sites (Table 2). Eighteen (38.3%) sites reported using two sputum
samples collected on the spot and early in the morning, 16 (34.0%)
used three sputum samples, 12 (25.5%) sites used at least one
sputum per patient, and 18 (38.3%) sites used other procedures.
Thirty-two sites (68.1%) had conventional chest X-ray and 7
(14.9%) digital X-ray. TST was available in 29 (61.7%) sites.
Mycobacterial culture was available in 44 (93.6%) sites (Table 2).
The most frequently available culture systems were solid media
based culture in 16 sites (36.4%) and liquid culture (MGIT 960,
Beckton Dickinson, USA) in 15 sites (34.1%). The semi-automated
molecular diagnostic assay Xpert MTB/RIF (Cepheid, USA) was
available in about half of the sites (23 sites, 48.9%). The average
turnaround time for a TB diagnosis was reported to range between
3 and 4 days (median 3 days, range 1–14) in smear-positive cases
and 8–9 days in smear-negative cases (median 7 days, range 1–30).
Details on the availability and use of diagnostics are presented in
Table S4.
TST was less frequently available in sites from East and
Southern Africa compared to other regions (25% and 28.6%,
versus 83.3% to 100%, P = 0.001, Table 2). The availability of all
other TB diagnostics varied across regions, but differences did not
reach statistical significance. TST was also more frequently
available in urban settings compared to peri-urban and rural
settings (71.0%, 14.3% and 50.0%; P = 0.017), as well as more
frequent in smaller sites with fewer TB cases (82.6% in sites with
fewer than 100 TB cases per year, compared to 44.4% and 33.3%
in sites with 100 to 1,000 and more than 1,000 cases; P = 0.014).
Use of diagnostics
Overall, sputum microscopy was done in 745 (75.7%) patients,
mycobacterial culture in 220 (23.9%), Xpert MTB/RIF in 120
(20.6%), and chest X-ray in 688 (69.7%, Table 3). Results were
similar when restricting the analysis to the 642 patients with
pulmonary TB: 574 patients (83.8%) had sputum microscopy, 137
(21.3%) mycobacterial culture, 83 (21.0%) Xpert MTB/RIF, and
460 patients (67.1%) had a chest X-ray. In sites where diagnostic
tools were available, the geographic region, degree of urbaniza-
tion, level of care and payment models were associated with their
use (Table 3). For example, culture was more frequently used in
sites from the Caribbean, Central and South America than in sites
from East Africa (66.2% versus 2.5%, P,0.0001). Mycobacterial
culture was also more frequently used in urban settings (27.3% in
urban settings versus 15.5% in peri-urban and 4.9% in rural
settings, P,0.0001).
Costs to patients, availability and use
In about half of sites services were free to patients (23 sites,
48.9%). In the other sites (24 sites, 51.1%), the median cost to
patients was 2.1 USD (12 sites, IQR 1.5–3.0) for sputum smear
microscopy, 25.0 USD (12 sites, IQR 13.7–40.7) for culture, 7.7
USD (20 sites, IQR 5.3–12.0) for chest radiographs, and 50.0
USD (3 sites, IQR 29.6–129.8) for Xpert MTB/RIF. The
availability of TB diagnostics was similar in sites providing services
for free compared to sites charging patients. But expensive
diagnostics (more than 20.0 USD per test) were more frequently
used in sites where patients did not have to pay for it.
Mycobacterial culture was used in 26.8% of patients from the
20 sites offering free cultures versus 20.8% in the other sites
(p = 0.033, Table 4). The same was true for Xpert MTB/RIF
(26.2% versus 15.2%, p = 0.001). In contrast, there was no
evidence that diagnostics such as sputum microscopy or chest X-
ray were more frequently used in sites providing services free of
charge (Table 4).
Screening practices before ART initiation
Forty-four (93.6%) sites reported following national guidelines
to screen suspected TB cases. Screening practices for active disease
included symptom screening (46 sites, 97.9%), chest X-ray (38
sites, 80.9%), sputum smear microscopy (37 sites, 78.7%), culture
(16 sites, 34.0%), TST (11 sites, 23.4%) and Xpert MTB/RIF (5
sites, 10.6%, Table S5). To examine the approach of physicians
and clinical officers to screen for TB, we confronted them with the
hypothetical scenario of an adult newly diagnosed with HIV. At
the 46 sites reporting symptom screening as part of their screening
practices, 43 (93.5%) physicians reported choosing symptom to
screen for TB. In contrast, less than a quarter of clinicians
mentioned using sputum smear microscopy and Xpert MTB/RIF
despite the fact that these diagnostics were part of the screening
practices at their site.
Discussion
We surveyed 47 ART sites in a global network of HIV adult
treatment programs. We found that the use of mycobacterial
culture for TB diagnosis was low despite its availability at most
sites, while Xpert MTB/RIF was both infrequently available and
used. Programs providing services free of charge were associated
with higher levels of use of the available diagnostic tools. Our
study builds on a smaller survey of the ART in Lower Income
Countries (ART-LINC) collaboration in 2008, which showed that
the availability of TB diagnostics varied widely across ART
programs [18]. The present study covered many additional sites
Tuberculosis Diagnostic Practices in ART Programs
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within the larger IeDEA network across Asia, Africa, the
Caribbean and Central and South America and offers a global
view on ART programs in the low and middle-income countries
heavily affected by the generalized HIV and TB epidemics. In this
study, we also collected and analyzed information on individual
patients and the clinical decision making by treating physicians
and clinical officers. This approach allowed us to study the
availability, use, and practice of TB diagnostics in parallel.
We found that TB diagnostics were not systematically used even
when available. This was illustrated by sputum microscopy and
mycobacterial culture, which were not necessarily used for the
diagnosis of pulmonary TB even in sites with access to these
diagnostics. The discrepancy between availability and use
underlines that programmatic issues are essential to the control
of TB in the HIV-positive population and need to be considered
when new TB diagnostic and screening tools become available in
ART programs. Lin and colleagues recently showed that not only
new tools are needed to improve TB control, but that the overall
quality of patient care and the reduction of patient loss before
diagnosis need to be considered as part of an overall implemen-
tation concept [25]. The low use of available tools could also be a
reflection of some sites performing culture or sputum microscopy
only in selected cases, such as treatment failure or relapse,
depending on their guidelines. It could also reflect breakdowns in
the supply chain for reagents, lack of local expertise on how to use
these tools, adherence to national guidelines, or the cost of the test.
The availability of diagnostic tools was similar in programs
providing tests free of charge and programs charging patients, but
some diagnostics were more frequently used where no costs to
patients were incurred. This was particularly true for the
automated molecular diagnostic assay Xpert MTB/RIF. It
appears that not only the distance to the diagnostic facility matters
[26], but also the costs of these diagnostics to the patients. Even if
the price of TB diagnostics such as Xpert MTB/RIF has been
reduced [27], the costs to the patients may still be prohibitive in
relation to their budget. Patients may face difficult choices when
balancing the costs of diagnostics with other demands on the
family budget. Having free TB diagnostics appears to be important
for the successful implementation of TB control in the HIV-
infected population.
Our study has several limitations. The results were based on a
survey mainly reflecting the situation during the study period as
reported by the site representatives. It is therefore difficult to
distinguish between intermittent or consistent availability and use.
However, we substantiated our findings by collecting data from
patient seen during the study period, and by assessing scenarios to
capture the clinical decision making of treating physicians and
clinical officers.
The ART programs participating in the IeDEA network may
not be representative of all ART programs in a country or region.
IeDEA sites tend to be located in urban settings, collect data using
electronic medical record systems and many of them participate in
Figure 1. Geographical distribution of the 47 ART programs the International epidemiologic Databases to Evaluate AIDS (IeDEA)
collaboration, which treat adults in lower income countries and participated in the survey project. The regions correspond to the IeDEA
regions. Countries with at least one site completing Section A of the questionnaire are shown. Numbers in parentheses indicate the number of adult
ART programs included in the analysis.
doi:10.1371/journal.pone.0077697.g001
Tuberculosis Diagnostic Practices in ART Programs
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e77697
T
a
b
le
1
.
C
h
ar
ac
te
ri
st
ic
s
o
f
4
7
ad
u
lt
A
R
T
p
ro
g
ra
m
s
fr
o
m
lo
w
e
r
in
co
m
e
co
u
n
tr
ie
s
an
d
9
8
7
ad
u
lt
p
at
ie
n
ts
se
e
n
d
u
ri
n
g
th
e
st
u
d
y
p
e
ri
o
d
in
th
e
p
ro
g
ra
m
s
p
ar
ti
ci
p
at
in
g
in
th
e
st
u
d
y.
C
h
a
ra
ct
e
ri
st
ic
A
ll
A
si
a
P
a
ci
fi
c
C
a
ri
b
b
e
a
n
-C
e
n
tr
a
l-
S
o
u
th
A
m
e
ri
ca
C
e
n
tr
a
l
A
fr
ic
a
E
a
st
A
fr
ic
a
S
o
u
th
e
rn
A
fr
ic
a
W
e
st
A
fr
ic
a
A
R
T
p
ro
g
ra
m
ch
a
ra
ct
e
ri
st
ic
s
N
u
m
b
e
r
o
f
si
te
s,
n
47
6
7
5
8
1
4
7
N
u
m
b
e
r
o
f
co
u
n
tr
ie
s,
n
26
4
7
4
3
5
3
Se
tt
in
g
,
n
(%
)
U
rb
an
38
(8
0.
8)
6
(1
0
0
)
7
(1
0
0
)
5
(1
0
0
)
4
(5
0
.0
)
1
0
(7
1
.4
)
6
(8
5
.7
)
P
e
ri
-u
rb
an
7
(1
4.
9)
2
(2
5
.0
)
4
(2
8
.6
)
1
(1
4
.3
)
R
u
ra
l
2
(4
.3
)
2
(2
5
.0
)
Le
ve
l
o
f
ca
re
,
n
(%
)
P
ri
m
ar
y
15
(3
1.
9)
1
(1
6
.7
)
2
(2
5
.0
)
1
0
(7
1
.4
)
2
(2
8
.6
)
Se
co
n
d
ar
y
8
(1
7)
0
1
(1
4
.3
)
2
(4
0
)
1
(1
2
.5
)
2
(1
4
.3
)
2
(2
8
.6
)
T
e
rt
ia
ry
24
(5
1.
1)
5
(8
3
.3
)
6
(8
5
.7
)
3
(6
0
)
5
(6
2
.5
)
2
(1
4
.3
)
3
(4
2
.8
)
T
re
at
in
g
ad
u
lt
s
an
d
ch
ild
re
n
,
n
(%
)
A
d
u
lt
s
an
d
ch
ild
re
n
32
(6
8.
1)
1
(1
6
.7
)
3
(4
2
.9
)
5
(1
0
0
)
6
(7
5
.0
)
1
2
(8
5
.7
)
5
(7
1
.4
)
A
d
u
lt
s
o
n
ly
15
(3
1.
9)
5
(8
.3
3
)
4
(5
7
.1
)
0
2
(2
5
.0
)
2
(1
4
.3
)
2
(2
8
.6
)
C
o
st
m
o
d
e
l
Fu
ll
p
ay
m
e
n
t
b
y
th
e
p
at
ie
n
t
2
(4
.3
)
2
(2
8
.6
)
C
o
st
sh
ar
in
g
(p
ar
ti
al
p
ay
m
e
n
t)
19
(4
0.
4)
3
(5
0
)
2
(2
8
.6
)
4
(8
0
)
2
(2
5
)
3
(2
1
.4
)
5
(7
1
.4
)
A
va
ila
b
le
at
n
o
co
st
fo
r
th
e
p
at
ie
n
t
23
(4
8.
9)
2
(3
3
.3
)
5
(7
1
.4
)
1
(2
0
)
6
(7
5
)
9
(6
4
.3
)
0
O
th
e
r
3
(6
.4
)
1
(3
3
.3
)
2
(1
4
.3
)
0
C
u
m
u
la
ti
ve
n
u
m
b
e
r
o
f
p
at
ie
n
ts
e
n
ro
lle
d
1
,
n
25
1,
37
7
8
,8
6
1
1
9
,0
2
9
1
1
,9
7
7
1
0
3
,9
5
4
7
6
,7
6
7
3
0
,7
8
9
N
e
w
T
B
ca
se
s
p
e
r
ye
ar
,
n
17
,7
48
2
9
6
1
,6
9
3
6
0
6
2
,1
3
4
1
2
,3
7
8
6
4
1
P
re
-A
R
T
T
B
(o
n
av
e
ra
g
e
)
2
,
m
e
d
ia
n
,
%
22
.9
2
6
3
3
.9
3
7
.8
1
0
.4
1
8
.9
2
2
.7
P
a
ti
e
n
t
ch
a
ra
ct
e
ri
st
ic
s
N
o
.
o
f
p
at
ie
n
ts
98
7
3
5
7
1
4
7
2
5
5
4
8
1
9
8
A
g
e
at
st
ar
t
o
f
A
R
T
,
m
e
d
ia
n
(I
Q
R
),
ye
ar
s
34
.7
(2
9.
4–
41
)
3
2
.7
(2
8
.6
–
3
7
.2
)
3
4
(2
7
.3
–
4
2
.4
)
3
7
.1
(3
0
.1
–
4
4
.6
)
3
5
.2
(2
9
.3
–
4
2
.3
)
3
4
.4
(2
9
.1
–
3
9
.6
)
3
6
.2
(3
1
.2
–
4
2
.2
)
Fe
m
al
e
se
x,
n
(%
)
44
2
(4
4.
8)
8
(2
2
.9
)
2
9
(4
0
.8
)
2
3
(4
0
.8
)
1
1
9
(4
6
.7
)
2
1
0
(4
3
.7
)
5
3
(5
4
.1
)
Si
te
o
f
d
is
e
as
e
,
n
(%
)
P
u
lm
o
n
ar
y
68
5
(6
9.
4)
2
4
(6
8
.6
)
5
6
(7
8
.9
)
2
3
(4
8
.9
)
1
9
8
(7
7
.6
)
3
2
8
(6
8
.2
)
5
6
(5
7
.1
)
Ex
tr
ap
u
lm
o
n
ar
y
29
3
(2
9.
7)
1
1
(3
1
.4
)
1
2
(1
6
.9
)
2
0
(4
2
.6
)
5
7
(2
2
.3
)
1
5
2
(3
1
.6
)
4
1
(4
1
.8
)
U
n
kn
o
w
n
9
(0
.9
)
0
3
(4
.2
)
4
(8
.5
)
0
1
(0
.2
)
1
(1
)
T
yp
e
o
f
T
B
p
at
ie
n
t,
n
(%
)
N
e
w
ca
se
86
3
(8
7.
4)
2
5
(7
1
.4
)
6
0
(8
4
.6
)
3
7
(7
8
.7
)
2
3
6
(9
2
.6
)
4
1
3
(8
5
.9
)
9
2
(9
3
.9
)
R
e
la
p
se
78
(7
.9
)
5
(1
4
.3
)
6
(8
.4
)
1
(2
.1
)
1
3
(5
.1
)
4
7
(9
.8
)
6
(6
.1
)
T
re
at
m
e
n
t
af
te
r
d
e
fa
u
lt
11
(1
.1
)
0
2
(2
.8
)
0
3
(1
.2
)
6
(1
.2
)
0
O
th
e
r
23
(2
.3
)
0
0
9
(1
9
.1
)
1
(0
.4
)
1
3
(2
.7
)
0
Tuberculosis Diagnostic Practices in ART Programs
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e77697
T
a
b
le
1
.
C
o
n
t.
C
h
a
ra
ct
e
ri
st
ic
A
ll
A
si
a
P
a
ci
fi
c
C
a
ri
b
b
e
a
n
-C
e
n
tr
a
l-
S
o
u
th
A
m
e
ri
ca
C
e
n
tr
a
l
A
fr
ic
a
E
a
st
A
fr
ic
a
S
o
u
th
e
rn
A
fr
ic
a
W
e
st
A
fr
ic
a
C
D
4
ce
ll
co
u
n
t
(c
e
lls
/ m
l)
1
A
t
ti
m
e
o
f
A
R
T
st
ar
t,
m
e
d
ia
n
(I
Q
R
)
12
7
(4
2
–
25
0)
5
8
(2
1
–
1
8
6
)
1
9
2
.5
(7
1
–
3
5
5
)
1
4
8
(4
9
–
3
3
6
)
1
0
5
(3
1
–
2
7
1
)
1
1
3
(4
2
–
2
1
7
)
1
6
3
.5
(7
3
–
2
8
1
)
M
is
si
n
g
o
b
se
rv
a
ti
o
n
s,
n
(%
)
15
8
(1
6.
1)
2
(5
.7
)
13
(1
8.
3)
12
(2
5.
6)
43
(1
6.
9)
84
(1
7.
5)
4
(4
.1
)
W
H
O
cl
in
ic
al
st
ag
e
1
,
n
(%
)
I
an
d
II
58
(6
.3
)
0
3
(4
.6
)
1
(2
.3
)
1
9
(7
.5
)
1
5
(3
.5
)
2
0
(2
1
.0
)
III
an
d
IV
86
3
(9
3.
7)
3
5
(1
0
0
)
6
3
(9
4
.4
)
4
2
(9
7
.7
)
2
3
4
(9
2
.5
)
4
1
4
(9
6
.5
)
7
5
(7
9
.0
)
M
is
si
n
g
o
b
se
rv
a
ti
o
n
s,
n
66
(6
.7
)
0
5
(7
)
4
(8
.6
)
2
(0
.8
)
5
2
(1
0
.8
)
3
(3
.1
)
P
re
vi
o
u
s
h
is
to
ry
o
f
T
B
,
n
(%
)
18
0
(1
8.
2)
0
4
9
(6
9
)
1
1
(2
3
.4
)
4
1
(1
6
.1
)
5
6
(1
1
.6
)
2
3
(2
3
.5
)
D
e
la
y
b
e
tw
e
e
n
T
B
d
ia
g
n
o
si
s
an
d
T
B
tr
e
at
m
e
n
t,
n
(%
)
W
it
h
in
2
d
ay
s
81
0
(8
2.
1)
2
3
(6
5
.7
)
6
0
(8
4
.5
)
4
7
(1
0
0
)
2
1
7
(8
5
.1
)
4
0
1
(8
3
.4
)
6
2
(6
3
.3
)
M
o
re
th
an
2
d
ay
s
17
7
(1
7.
9)
1
2
(3
4
.3
)
1
1
(1
5
.5
)
3
8
(1
4
.9
)
8
0
(1
6
.6
)
3
6
(3
6
.7
)
M
e
d
ia
n
d
e
la
y
b
e
tw
e
e
n
T
B
tr
e
at
m
e
n
t
an
d
A
R
T
2
,
d
ay
s,
(I
Q
R
)
37
(1
5–
12
4)
1
8
.5
(1
1
–
3
0
)
1
7
(1
4
–
6
8
)
3
3
(2
7
–
1
2
7
)
6
3
(3
1
–
1
5
0
)
4
1
.5
(1
7
–
1
2
9
)
3
6
(3
2
–
8
5
)
T
B
tr
e
at
m
e
n
t
b
e
fo
re
e
n
ro
lm
e
n
t
to
A
R
T
38
8
(3
9.
1)
2
6
(7
4
.3
)
4
1
(5
7
.7
)
1
5
(3
1
.9
)
5
1
(2
0
.0
)
2
4
6
(5
1
.1
)
9
(9
.2
)
A
R
T
,
an
ti
re
tr
o
vi
ra
l
tr
e
at
m
e
n
t;
T
B
,
tu
b
e
rc
u
lo
si
s;
SM
S:
Sh
o
rt
M
e
ss
ag
e
Se
rv
ic
e
.
1
fo
llo
w
e
d
-u
p
at
ti
m
e
o
f
su
rv
e
y.
2
p
ro
p
o
rt
io
n
o
f
ad
u
lt
s
w
it
h
p
re
vi
o
u
s
h
is
to
ry
o
f
T
B
b
e
fo
re
st
ar
ti
n
g
A
R
T
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
7
7
6
9
7
.t
0
0
1
Tuberculosis Diagnostic Practices in ART Programs
PLOS ONE | www.plosone.org 6 October 2013 | Volume 8 | Issue 10 | e77697
additional research projects outside the IeDEA collaboration. Of
note, a recent survey of HIV care centers in sub-Saharan Africa
within the International Center for AIDS Care and Treatment
Programs (ICAP)-Columbia University program showed a lower
availability of TB diagnostics such as sputum smear microscopy
and culture than in our study [28]. This might be explained by the
nature of the ICAP program, which consisted of a larger
proportion of smaller sites in rural settings, compared to the
IeDEA collaboration, which included larger sites in urban settings
[21]. Unfortunately, there are only few studies examining
availability and use of TB diagnostics in ART programs in low
and middle-income countries, which limits the potential for
comparisons with other settings. Another limitation is that the
analysis of individual patient data was based on those having been
diagnosed with TB, rather than those suspected of having TB,
although the latter case was addressed in a hypothetical case
scenario. Finally, we cannot exclude that the answers provided by
the clinicians in the scenarios strictly represented the current
practice in their ART program.
In conclusion, we found that access to and use of TB diagnostics
is still limited in ART programs and that tests are not
systematically used, even when available. Improved diagnostic
capacities are necessary for better patient care, to increase TB case
retention, reduce delays before treatment initiation, and thereby
reducing the risk of onward transmission. Our study suggests that
the availability of diagnostics alone does not automatically lead to
their use at the patient level, particularly if not free of charge to
patients.
Our report underlines the challenges of implementing TB
diagnostics in the field. Therefore, when implementing TB
diagnostics, our study suggests that it is crucial to consider the
affordability of diagnostic tests, the supply chain of reagents,
training of laboratory staff, short distances to diagnostic facilities,
and prompt access to TB care for diagnosed patients [25,29].
Further studies need to focus on the barriers preventing access to
TB diagnostics and their adequate use. This may have implica-
tions for the situation in ART programs as well as TB care centers
outside of ART programs. In the meantime, we will continue to
Table 2. Program-level characteristics associated with the availability of sputum smear microscopy, culture, chest X-ray, Xpert
MTB/RIF, and tuberculin skin testing (TST) in 47 ART programs treating adults in lower income countries.
Program-level characteristic Sputum microscopy Culture Chest X-ray Xpert MTB/RIF TST
n (%) P value n (%) P value n (%) P value n (%) P value n (%) P value
Total 47 (100) 44 (93.6) 47 (100) 23 (48.9) 29 (61.7)
IeDEA region – 0.63 – 0.41 0.001
Asia-Pacific 6 6 (100) 6 4 (66.7) 5 (83.3)
Caribbean-Central-South America 7 7 (100) 7 2 (28.6) 6 (85.7)
Central Africa 5 4 (80.0) 5 1 (20.0) 5 (100)
East Africa 8 7 (87.5) 8 4 (50.0) 2 (25.0)
Southern Africa 14 13 (92.9) 14 9 (64.3) 4 (28.6)
West Africa 7 7 (100) 7 3 (42.9) 7 (100)
Setting – 0.62 – 0.89 0.017
Urban 38 36 (95.7) 38 18 (47.4) 27 (71.0)
Peri-urban 7 6 (85.7)) 7 4 (57.1) 1 (14.3)
Rural 2 2 (100) 2 1 (50.0) 1 (50.0)
Level of care – 0.71 – 0.70 0.32
Primary 15 14 (93.3) 15 7 (46.7) 7 (46.7)
Secondary 8 7 (87.5) 8 3 (37.5) 5 (62.5)
Tertiary 24 23 (95.8) 24 13 (54.2) 17 (70.8)
Treating adults and children – 0.22 – 0.68 0.077
Adults and children 15 15 (100) 15 8 (53.3) 12 (80.0)
Adults only 32 29 (90.6) 32 15 (46.8) 17 (53.1)
Cumulative number of adults enrolled in
HIV care 1
– 0.65 – 0.27 0.12
Below 1,000 5 5 (100) 5 3 (60.0) 3 (60.0)
1,001 to 10,000 37 34 (91.9) 37 16 (43.2) 25 (67.6)
10,001 to 20,000 5 5 (100) 5 4 (80.0) 1 (20.0)
New TB cases per year, n – 0.19 – 0.74 0.014
Below 100 23 20 (86.7) 23 10 (43.5) 19 (82.6)
100 to 1,000 18 18 (100) 18 10 (55.6) 8 (44.4)
.1,000 6 6 (100) 6 3 (50.0) 2 (33.3)
ART, antiretroviral treatment; TB, tuberculosis; TST, tuberculin skin test.
Chi square tests were used to calculate P values.
1followed-up at time of survey.
doi:10.1371/journal.pone.0077697.t002
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monitor availability and use of diagnostics in ART programs in
resource limited settings.
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